Vydura®▼ (rimegepant) | Current Migraine Treatment Limitations

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

About

Current Migraine Treatment Limitations

Mechanism of Action

Efficacy

Study Designs

Acute Treatment

Preventive Treatment

Safety

Dosing

Prescribing Information

Supporting Resources

Patient Resources

Current Migraine Treatment Limitations

Patients with migraine on average take 3+ medications, and there are limitations to those treatments^1–4:

About

Efficacy⁵

Approximately 30%-40% of people with migraine are not successfully treated using a triptan, for reasons of insufficient efficacy and/or tolerability

Durability⁶

In a review of clinical studies, only 18%-33% of patients achieve sustained freedom from pain at 24 hours, and 20%-34% of patients require rescue medication

Medication-Overuse Headache⁷

Frequent use of medication for the acute treatment of migraine attacks can lead to medication-overuse headache (MOH)

Tolerability^8,9

Oral preventive treatments like anticonvulsants and beta-blockers are associated with AEs such as weight gain, fatigue and cognitive issues

Patient Medication Preference¹⁰

In a survey of 372 patients with migraine, more would prefer to take a pill (60.6%) as a preventive treatment than an injection (39.5%).

Contraindications¹¹

11% of patients with migraine have a history of cardiovascular events that make them unsuitable for triptans

Please refer to the VYDURA®▼Summary of Product Characteristics for full prescribing information

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References:

Ferrari A, Baraldi C, Licata M, Rustichelli C. Polypharmacy among headache patients: a cross-sectional study. CNS Drugs. 2018;32(6):567-578.

Burch R. Preventive migraine treatment. [published correction appears in Continuum I. 2-21;27(5):1494-1495.] Continuum (Minneap Minn). 2021;27(3):613-632.

Moreno-Ajona D, Chan C, Villar-Martínez MD, Goadsby PJ. Targeting CGRP and 5-HT1F receptors for the acute therapy of migraine: a literature review. Headache. 2019;59(suppl 2):3-19.

Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011;83(3):271-280. Erratum in: Am Fam Physician. 2011;84(7):738.

Leroux E, Buchanan A, Lombard L, et al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020;37(12):4765-4796.

Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221-235.

VYDURA (rimegepant) Summary of Product Characteristics.

Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society [published correction appears in Neurology. 2013;80(9):871]. Neurology. 2012;78(17):1337-1345.

Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo controlled trial. Lancet. 2021;397(10268):51-60.

Mitsikostas DD, Belesioti I, Arvaniti C, et al. Patients’ preferences for headache acute and preventive treatment. J Headache Pain. 2017;18(1):102.

Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300-1311.

Legal Category: S1B
Further information is available upon request

PP-NNT-IRL-0116. October 2024

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

PP-UNP-IRL-0891. February 2025

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0891. February 2025